$1.49 Million is the total value of Cormorant Asset Management, LP's 73 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 72.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RXDX | Buy | PROMETHEUS BIOSCIENCES INC | $229,900 | -99.8% | 2,090,000 | +5.6% | 15.38% | +88.5% |
| APLS | Buy | APELLIS PHARMACEUTICALS INC | $81,540 | -99.9% | 1,576,872 | +6.7% | 5.46% | -22.7% |
| RNA | Buy | AVIDITY BIOSCIENCES INC | $61,291 | -99.8% | 2,762,115 | +37.3% | 4.10% | +78.5% |
| DSGN | Buy | DESIGN THERAPEUTICS INC | $52,839 | -99.9% | 5,150,000 | +3.0% | 3.54% | -39.5% |
| Buy | ERASCA INC | $46,605 | -99.9% | 10,813,246 | +2.9% | 3.12% | -45.5% | |
| Buy | VENTYX BIOSCIENCES INC | $35,434 | -99.9% | 1,080,643 | +38.4% | 2.37% | +24.5% | |
| ETNB | New | 89BIO INC | $32,462 | – | 2,550,000 | +100.0% | 2.17% | – |
| BCAB | Buy | BIOATLA INC | $30,363 | -99.8% | 3,680,365 | +68.7% | 2.03% | +73.1% |
| AXSM | New | AXSOME THERAPEUTICS INC | $25,067 | – | 325,000 | +100.0% | 1.68% | – |
| Buy | ASTRIA THERAPEUTICS INC | $24,569 | -99.8% | 1,650,000 | +37.5% | 1.64% | +116.9% | |
| RAIN | Buy | RAIN ONCOLOGY INC | $23,829 | -99.8% | 2,978,660 | +28.0% | 1.60% | +100.9% |
| CABA | Buy | CABALETTA BIO INC | $18,239 | -97.6% | 1,971,739 | +70.8% | 1.22% | +2246.2% |
| PCVX | New | VAXCYTE INC | $15,584 | – | 325,000 | +100.0% | 1.04% | – |
| New | PRIME MEDICINE INC | $13,644 | – | 734,350 | +100.0% | 0.91% | – | |
| IMVT | New | IMMUNOVANT INC | $7,100 | – | 400,000 | +100.0% | 0.48% | – |
| ALT | New | ALTIMMUNE INCcall | $6,580 | – | 400,000 | +100.0% | 0.44% | – |
| VKTX | New | VIKING THERAPEUTICS INC | $6,580 | – | 700,000 | +100.0% | 0.44% | – |
| XFOR | Buy | X4 PHARMACEUTICALS INC | $1,618 | -99.9% | 1,628,980 | +96.1% | 0.11% | +9.1% |
| New | BIOHAVEN LTD | $1,138 | – | 81,963 | +100.0% | 0.08% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
| 4 | 2024-03-11 |
| 13F-HR | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.